MedTrace Logo

Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes

NCT00628056 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2008-03-04

No results posted yet for this study

Summary

Diabetes increases the risk of heart failure. This is mainly due to a disease of the blood vessels supplying the heart muscle and/or high blood pressure, but abnormal metabolism may also contribute. We plan to study the mechanisms involved in this abnormal metabolism, whilst also assessing the effects of a drug called Perhexiline which improves the abnormal metabolism that is present in diabetic patients before the development of heart failure.

Conditions

  • Diabetic Cardiomyopathy

Interventions

DRUG

Perhexiline

Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • University Hospital Birmingham

    lead OTHER

Principal Investigators

  • Michael Frenneaux, MD FRCP FACC · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00628056 on ClinicalTrials.gov